scholarly journals Antioxidation of Cerium Oxide Nanoparticles to Several Series of Oxidative Damage Related to Type II Diabetes Mellitus In Vitro

2016 ◽  
Vol 22 ◽  
pp. 3792-3797 ◽  
Author(s):  
Jing-hui Zhai ◽  
Yi Wu ◽  
Xiao-ying Wang ◽  
Yue Cao ◽  
Kan Xu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Oxidative Damage ◽  
Cerium Oxide ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Cerium Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Type Ii

scholarly journals The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus

2017 ◽  
Vol 2017 ◽  
pp. 1-15 ◽  
Author(s):  
Joshua A. David ◽  
William J. Rifkin ◽  
Piul S. Rabbani ◽  
Daniel J. Ceradini
Keyword(s):  
Diabetes Mellitus ◽  
Oxidative Damage ◽  
Therapeutic Target ◽  
Type Ii Diabetes ◽  
Animal Studies ◽  
Cell Types ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
And Oxidative Stress

Despite improvements in awareness and treatment of type II diabetes mellitus (TIIDM), this disease remains a major source of morbidity and mortality worldwide, and prevalence continues to rise. Oxidative damage caused by free radicals has long been known to contribute to the pathogenesis and progression of TIIDM and its complications. Only recently, however, has the role of the Nrf2/Keap1/ARE master antioxidant pathway in diabetic dysfunction begun to be elucidated. There is accumulating evidence that this pathway is implicated in diabetic damage to the pancreas, heart, and skin, among other cell types and tissues. Animal studies and clinical trials have shown promising results suggesting that activation of this pathway can delay or reverse some of these impairments in TIIDM. In this review, we outline the role of oxidative damage and the Nrf2/Keap1/ARE pathway in TIIDM, focusing on current and future efforts to utilize this relationship as a therapeutic target for prevention, prognosis, and treatment of TIID.

scholarly journals Increased oxidative damage to all DNA bases in patients with type II diabetes mellitus

FEBS Letters ◽  
1999 ◽  
Vol 448 (1) ◽  
pp. 120-122 ◽  
Author(s):  
Almas Rehman ◽  
Jaffar Nourooz-Zadeh ◽  
Wenke Möller ◽  
Hans Tritschler ◽  
Paulo Pereira ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Oxidative Damage ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Dna Bases ◽  
Type Ii

DOPAMINE ACTIVITY AND OMAPATRILAT, “IN VITRO”, AND IN AN EXPERIMENTAL MODEL OF TYPE II DIABETES MELLITUS (DM-II) WITH KIDNEY DAMAGE

2000 ◽  
Vol 18 ◽  
pp. S144
Author(s):  
R. García-Robles ◽  
F. Villalba-Díaz ◽  
O. González-Albarrán ◽  
S. Calvo ◽  
O. Gómez ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Experimental Model ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Kidney Damage ◽  
Type Ii

scholarly journals Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Fauze Camargo Maluf ◽  
David Feder ◽  
Alzira Alves de Siqueira Carvalho
Keyword(s):  
Diabetes Mellitus ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Alpha Synuclein ◽  
Peroxisome Proliferator ◽  
Type Ii ◽  
Peroxisome Proliferator Activated Receptor

In the early sixties, a discussion started regarding the association between Parkinson’s disease (PD) and type II diabetes mellitus (T2DM). Today, this potential relationship is still a matter of debate. This review aims to analyze both diseases concerning causal relationships and treatments. A total of 104 articles were found, and studies on animal and “in vitro” models showed that T2DM causes neurological alterations that may be associated with PD, such as deregulation of the dopaminergic system, a decrease in the expression of peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α), an increase in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 (PED/PEA-15), and neuroinflammation, as well as acceleration of the formation of alpha-synuclein amyloid fibrils. In addition, clinical studies described that Parkinson’s symptoms were notably worse after the onset of T2DM, and seven deregulated genes were identified in the DNA of T2DM and PD patients. Regarding treatment, the action of antidiabetic drugs, especially incretin mimetic agents, seems to confer certain degree of neuroprotection to PD patients. In conclusion, the available evidence on the interaction between T2DM and PD justifies more robust clinical trials exploring this interaction especially the clinical management of patients with both conditions.

The effect of Milgamma NR and SperminR on in vitro cellular immune reactions in patients with type II diabetes mellitus

1997 ◽  
Vol 56 ◽  
pp. 482
Author(s):  
M. Horváth ◽  
Cs. Keszthelyi ◽  
M.N. Vers ◽  
P. Kempler ◽  
A. Marton ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Immune Reactions ◽  
Cellular Immune
Sign in / Sign up

Export Citation Format

Share Document